Available Technologies

Browse Penn-owned technologies available for licensing.

Anti-RGS12 antibody for treatment of Rheumatoid Arthritis and Osteoporosis


Rheumatoid Arthritis (RA) affects between 0.5-1% of Americans with symptoms ranging from stiffness to permanent joint damage and disability. There are no effective treatments currently available for RA patients.


To fill this unmet need, the researchers Drs. Yang and Yuan have developed an antibody to block the activity of Regulator of G- Protein- Signaling Protein 12 (RGS-12). This protein plays a critical role in the inflammatory response in macrophages. When over-activated, this protein causes inflammation in the joint and bone degeneration by regulating cytokine expression.

This invention consists of the antibody directed against RGS12, delivered with or without nanoparticles that can be injected into the affected joints or systematically. Upon delivery, the antibody blocks the bone resorption and inflammatory activities, resulting in less painful swelling and increased bone density and protect bone erosion.

In mouse models, the anti-inflammatory effects of this therapy are shown to be more effective than the current standard of care, Celecoxib. This technology’s antibody-based treatment also causes fewer side effects and is less toxic than conventional drugs. RA patients and those suffering from osteoporosis could see improved outcomes with this therapy.


  • More effective than Celecoxib
  • Inhibits inflammation
  • Increases bone density


  • Development of an effective RA therapy
  • Prevention of osteoporosis

RGS12 is a novel critical NF-kappa B activator involved in diseases such as Rheumatoid Arthritis (RA). By blocking this protein, researchers have successfully treated this condition in RA mice (figure A). Paw thickness, an indication of RA in mice, was significantly decreased in the treatment group (figure B). 

Stage of Development: 

  • Antibody have been produced, used in vivo and in vitro experiments
  • Researchers will begin dose and administration routes optimization to find most effective and safe dose and administration route.
  • Test for more medical indicators (TNF, IL1, IL6, Cox2) and joint and bone pathogenesis after drug delivery
  • Test for the safety and side effects

Intellectual Property: 

US Provisional Filing

Reference Media: 

  • Yuan et al. Cell Death and Diff, 2015, 22(12)
  • Malmstrom et al. Nature- Immunology, 2016, 17(60)
  • Myasoedova et al. Arthritis Rheum, 2010, 62(6)

Desired Partnerships: 

  • License
  • Co-development

Patent Information:


Docket # 18-8586

For Information, Contact:

Melissa Kelly Associate Director
University of Pennsylvania